Role of Colchicine in Cardiovascular Disease Management
Arterioscler Thromb Vasc Biol. 2024 Mar 21. doi: 10.1161/ATVBAHA.124.319851. Online ahead of print.ABSTRACTColchicine-an anti-inflammatory alkaloid-has assumed an important role in the management of cardiovascular inflammation ≈3500 years after its first medicinal use in ancient Egypt. Primarily used in extremely high doses for the treatment of acute gout flares during the 20th century, research in the early 21st century demonstrated that low-dose colchicine effectively treats acute gout attacks, lowers the risk of recurrent pericarditis, and can even add to secondary prevention of major adverse cardiovascular events. As...
Source: Atherosclerosis - March 21, 2024 Category: Cardiology Authors: Leo F Buckley Peter Libby Source Type: research
Role of Colchicine in Cardiovascular Disease Management
Arterioscler Thromb Vasc Biol. 2024 Mar 21. doi: 10.1161/ATVBAHA.124.319851. Online ahead of print.ABSTRACTColchicine-an anti-inflammatory alkaloid-has assumed an important role in the management of cardiovascular inflammation ≈3500 years after its first medicinal use in ancient Egypt. Primarily used in extremely high doses for the treatment of acute gout flares during the 20th century, research in the early 21st century demonstrated that low-dose colchicine effectively treats acute gout attacks, lowers the risk of recurrent pericarditis, and can even add to secondary prevention of major adverse cardiovascular events. As...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - March 21, 2024 Category: Cardiology Authors: Leo F Buckley Peter Libby Source Type: research
Role of Colchicine in Cardiovascular Disease Management
Arterioscler Thromb Vasc Biol. 2024 Mar 21. doi: 10.1161/ATVBAHA.124.319851. Online ahead of print.ABSTRACTColchicine-an anti-inflammatory alkaloid-has assumed an important role in the management of cardiovascular inflammation ≈3500 years after its first medicinal use in ancient Egypt. Primarily used in extremely high doses for the treatment of acute gout flares during the 20th century, research in the early 21st century demonstrated that low-dose colchicine effectively treats acute gout attacks, lowers the risk of recurrent pericarditis, and can even add to secondary prevention of major adverse cardiovascular events. As...
Source: Atherosclerosis - March 21, 2024 Category: Cardiology Authors: Leo F Buckley Peter Libby Source Type: research
Role of Colchicine in Cardiovascular Disease Management
Arterioscler Thromb Vasc Biol. 2024 Mar 21. doi: 10.1161/ATVBAHA.124.319851. Online ahead of print.ABSTRACTColchicine-an anti-inflammatory alkaloid-has assumed an important role in the management of cardiovascular inflammation ≈3500 years after its first medicinal use in ancient Egypt. Primarily used in extremely high doses for the treatment of acute gout flares during the 20th century, research in the early 21st century demonstrated that low-dose colchicine effectively treats acute gout attacks, lowers the risk of recurrent pericarditis, and can even add to secondary prevention of major adverse cardiovascular events. As...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - March 21, 2024 Category: Cardiology Authors: Leo F Buckley Peter Libby Source Type: research
Role of Colchicine in Cardiovascular Disease Management
Arterioscler Thromb Vasc Biol. 2024 Mar 21. doi: 10.1161/ATVBAHA.124.319851. Online ahead of print.ABSTRACTColchicine-an anti-inflammatory alkaloid-has assumed an important role in the management of cardiovascular inflammation ≈3500 years after its first medicinal use in ancient Egypt. Primarily used in extremely high doses for the treatment of acute gout flares during the 20th century, research in the early 21st century demonstrated that low-dose colchicine effectively treats acute gout attacks, lowers the risk of recurrent pericarditis, and can even add to secondary prevention of major adverse cardiovascular events. As...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - March 21, 2024 Category: Cardiology Authors: Leo F Buckley Peter Libby Source Type: research
Role of Colchicine in Cardiovascular Disease Management
Arterioscler Thromb Vasc Biol. 2024 Mar 21. doi: 10.1161/ATVBAHA.124.319851. Online ahead of print.ABSTRACTColchicine-an anti-inflammatory alkaloid-has assumed an important role in the management of cardiovascular inflammation ≈3500 years after its first medicinal use in ancient Egypt. Primarily used in extremely high doses for the treatment of acute gout flares during the 20th century, research in the early 21st century demonstrated that low-dose colchicine effectively treats acute gout attacks, lowers the risk of recurrent pericarditis, and can even add to secondary prevention of major adverse cardiovascular events. As...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - March 21, 2024 Category: Cardiology Authors: Leo F Buckley Peter Libby Source Type: research
Role of Colchicine in Cardiovascular Disease Management
Arterioscler Thromb Vasc Biol. 2024 Mar 21. doi: 10.1161/ATVBAHA.124.319851. Online ahead of print.ABSTRACTColchicine-an anti-inflammatory alkaloid-has assumed an important role in the management of cardiovascular inflammation ≈3500 years after its first medicinal use in ancient Egypt. Primarily used in extremely high doses for the treatment of acute gout flares during the 20th century, research in the early 21st century demonstrated that low-dose colchicine effectively treats acute gout attacks, lowers the risk of recurrent pericarditis, and can even add to secondary prevention of major adverse cardiovascular events. As...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - March 21, 2024 Category: Cardiology Authors: Leo F Buckley Peter Libby Source Type: research
Validation of the Diagnostic Criteria for IgG4-Related Periaortitis/Periarteritis and Retroperitoneal Fibrosis (IgG4PA/RPF) 2018, and Proposal of a Revised 2023 Version for IgG4-Related Cardiovascular/Retroperitoneal Disease
CONCLUSIONS: Proposed 2023 revised IgG4-related cardiovascular/retroperitoneal disease criteria show significantly enhanced sensitivity while preserving high specificity, achieved through the inclusion of new items in radiologic, pathological, and extra-cardiovascular/retroperitoneal organ categories.PMID:38494710 | DOI:10.1253/circj.CJ-24-0026 (Source: Circulation Journal)
Source: Circulation Journal - March 18, 2024 Category: Cardiology Authors: Ichiro Mizushima Noriyasu Morikage Eisaku Ito Fuminori Kasashima Yasushi Matsumoto Naoki Sawa Hajime Yoshifuji Takako Saeki Yukako Shintani-Domoto Shogo Shimada Toshio Takayama Eisuke Amiya Makiko Ozawa Masaaki Takahashi Yasunari Fujinaga Takahiro Katsuma Source Type: research
Validation of the Diagnostic Criteria for IgG4-Related Periaortitis/Periarteritis and Retroperitoneal Fibrosis (IgG4PA/RPF) 2018, and Proposal of a Revised 2023 Version for IgG4-Related Cardiovascular/Retroperitoneal Disease
CONCLUSIONS: Proposed 2023 revised IgG4-related cardiovascular/retroperitoneal disease criteria show significantly enhanced sensitivity while preserving high specificity, achieved through the inclusion of new items in radiologic, pathological, and extra-cardiovascular/retroperitoneal organ categories.PMID:38494710 | DOI:10.1253/circj.CJ-24-0026 (Source: Circulation Journal)
Source: Circulation Journal - March 18, 2024 Category: Cardiology Authors: Ichiro Mizushima Noriyasu Morikage Eisaku Ito Fuminori Kasashima Yasushi Matsumoto Naoki Sawa Hajime Yoshifuji Takako Saeki Yukako Shintani-Domoto Shogo Shimada Toshio Takayama Eisuke Amiya Makiko Ozawa Masaaki Takahashi Yasunari Fujinaga Takahiro Katsuma Source Type: research
Validation of the Diagnostic Criteria for IgG4-Related Periaortitis/Periarteritis and Retroperitoneal Fibrosis (IgG4PA/RPF) 2018, and Proposal of a Revised 2023 Version for IgG4-Related Cardiovascular/Retroperitoneal Disease
CONCLUSIONS: Proposed 2023 revised IgG4-related cardiovascular/retroperitoneal disease criteria show significantly enhanced sensitivity while preserving high specificity, achieved through the inclusion of new items in radiologic, pathological, and extra-cardiovascular/retroperitoneal organ categories.PMID:38494710 | DOI:10.1253/circj.CJ-24-0026 (Source: Circulation Journal)
Source: Circulation Journal - March 18, 2024 Category: Cardiology Authors: Ichiro Mizushima Noriyasu Morikage Eisaku Ito Fuminori Kasashima Yasushi Matsumoto Naoki Sawa Hajime Yoshifuji Takako Saeki Yukako Shintani-Domoto Shogo Shimada Toshio Takayama Eisuke Amiya Makiko Ozawa Masaaki Takahashi Yasunari Fujinaga Takahiro Katsuma Source Type: research
Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373)
Vaccine. 2024 Mar 16:S0264-410X(24)00323-2. doi: 10.1016/j.vaccine.2024.03.036. Online ahead of print.ABSTRACTA benefit-risk assessment of NVX-CoV2373, a vaccine to prevent COVID-19, was conducted to determine if the benefits of vaccination outweigh the risks of myocarditis/pericarditis. This analysis used data on myocarditis/pericarditis cases observed in the NVX-CoV2373 clinical studies, real-world data of mRNA COVID vaccine effectiveness against predominant SARS-CoV-2 strains in early 2023, and recent COVID-19 burden of disease data from the United States. The benefits of NVX-CoV2373 vaccination were estimated as the nu...
Source: Vaccine - March 17, 2024 Category: Allergy & Immunology Authors: Jonathan Fix T Christopher Mast Katherine Smith Nicole Baker Source Type: research
